Advertisement
DXCM vs ISRG
Which Stock Would AI Choose? DexCom (DXCM) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- DXCM is riding stronger near-term momentum, with raised full-year guidance and positive clinical catalysts, while ISRG faces slowing U.S. procedure growth and a one-time litigation charge.
- Both are large-cap healthcare device leaders, but they serve different markets: diabetes management (DXCM) versus robotic-assisted surgery (ISRG).
- Tickeron AI Verdict: Based on observable trend consistency, catalysts, and relative positioning, Tickeron's AI currently favors DXCM over ISRG.
- DXCM has outperformed the broader market year-to-date, whereas ISRG has declined significantly from its early-2026 peak.
- For deeper context, explore DXCM Major News and DXCM Today's Price Move, plus ISRG Major News and ISRG Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Introduction
DexCom and Intuitive Surgical are two of the most closely followed medical-technology companies in the U.S. market, yet they operate in fundamentally different corners of healthcare. DexCom (DXCM) is a leader in continuous glucose monitoring (CGM) for diabetes care, while Intuitive Surgical (ISRG) dominates robotic-assisted surgery. This stock comparison is relevant for growth-oriented investors and traders weighing medical-device exposure, because the two names have diverged sharply in recent months in both performance and sentiment. Understanding their relative momentum, catalysts, and risk profiles can help market participants assess where AI-driven systems and human analysts see the more durable opportunity in the current environment.
DXCM Overview and Recent Performance
DexCom designs and commercializes CGM systems, including its G7 platform, used primarily by people with diabetes to track glucose levels in real time. In recent weeks, the company has benefited from a combination of strong fundamentals and favorable clinical news. Third-quarter revenue rose roughly 11% year over year to about $1.34 billion, with U.S. sales up around 14%, driven by share gains and growing adoption among people with type 2 diabetes, including non-insulin users. Adjusted earnings per share (EPS) came in ahead of consensus, and management modestly raised full-year revenue and margin guidance.
Sentiment has also been supported by the publication of the company's CONNECT clinical study in a leading medical journal, which investors view as a potential catalyst for broader Medicare and commercial reimbursement coverage. The continued rollout of the longer-wear G7 15 Day sensor and a newly authorized share repurchase program have reinforced confidence. As a result, DXCM has outperformed the broader market in recent months, with strong year-to-date gains relative to its industry group.
ISRG Overview and Recent Performance
Intuitive Surgical is the global leader in robotic-assisted minimally invasive surgery, best known for its da Vinci systems and the Ion endoluminal platform used in lung biopsies. The company's recent results were strong on the surface: third-quarter revenue climbed about 22% year over year to roughly $3.05 billion, and adjusted EPS beat expectations. System placements also rose, with the newer da Vinci 5 accounting for more than half of placements.
However, the market focused on softer signals. U.S. da Vinci procedure growth slowed to around 10%, which management and analysts described as its weakest pace in years, and the company narrowed its full-year procedure growth outlook. Intuitive Surgical also took a $450 million pre-tax charge related to an antitrust class-action settlement and disclosed planned pricing actions expected to reduce instrument revenue per procedure by roughly 3% to 5%. These factors contributed to a sharp post-earnings decline, and ISRG has fallen substantially year-to-date despite continued revenue growth.
Trending AI Robots
Tickeron maintains a marketplace of hundreds of AI trading bots that collectively monitor and trade thousands of different tickers across a range of strategies, timeframes, and risk profiles. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots section that highlights the systems best aligned with current conditions. These bots differ in trading style, holding period, performance statistics, and the sets of tickers they follow, allowing users to review them side by side. For readers evaluating names like DXCM and ISRG, exploring the curated list can offer an additional data-driven perspective on how automated systems are positioning across the market.
Head-to-Head Comparison
The core contrast between these companies lies in their growth drivers and near-term momentum. DexCom's business is anchored in a recurring, consumable sensor model tied to a large and expanding diabetic population, with reimbursement expansion representing a clear, quantifiable catalyst. Intuitive Surgical operates a "razor-and-blade" model built on system placements plus recurring instrument and accessory revenue, but its near-term story is complicated by deliberate price concessions and softer U.S. procedure volume.
Momentum also diverges. DXCM has shown relative strength, with upward guidance revisions and favorable clinical validation, whereas ISRG has been pressured by slowing growth optics, a legal settlement, and competitive and pricing headwinds. On valuation, both carry premium multiples, but ISRG trades well below its historical range after its 2026 pullback, while DXCM's multiple has expanded amid its rally. Risk profiles differ accordingly: DXCM faces competition and reimbursement uncertainty, while ISRG faces competition in robotics and questions about how quickly pricing actions convert into volume growth.
Tickeron AI Verdict
Weighing trend consistency, recent catalysts, and relative market positioning, Tickeron's AI currently leans toward DXCM as the more favorable of the two tickers in this comparison. The preference is driven by observable factors: DXCM's upward guidance revisions, expanding addressable market tied to type 2 diabetes coverage, and stronger relative price performance, versus ISRG's slowing U.S. procedure growth, pricing concessions, and legal charge. This assessment is probabilistic rather than definitive, reflecting the data available at the time of analysis, and conditions can shift as new earnings, reimbursement decisions, or competitive developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and ISRG is a StrongBuy.
DXCM saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DXCM moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 48 of the 62 cases the stock moved lower. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Aroon Indicator for ISRG shows an upward move is likely
ISRG's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 264 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 264 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 45 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on November 04, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 9 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 24%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 62 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.805) is normal, around the industry mean (4.964). P/E Ratio (51.222) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
DXCM | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 27 | 51 | |
PRICE GROWTH RATING 1..100 | 45 | 44 | |
P/E GROWTH RATING 1..100 | 53 | 80 | |
SEASONALITY SCORE 1..100 | 5 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (78) in the Medical Specialties industry is in the same range as DXCM (83). This means that ISRG’s stock grew similarly to DXCM’s over the last 12 months.
ISRG's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for DXCM (100). This means that ISRG’s stock grew somewhat faster than DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is in the same range as ISRG (51). This means that DXCM’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Price Growth Rating (44) in the Medical Specialties industry is in the same range as DXCM (45). This means that ISRG’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's P/E Growth Rating (53) in the Medical Specialties industry is in the same range as ISRG (80). This means that DXCM’s stock grew similarly to ISRG’s over the last 12 months.
| DXCM | ISRG | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 24% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 70% | 5 days ago 58% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 75% | 3 days ago 66% |
| Advances ODDS (%) | 7 days ago 67% | 5 days ago 67% |
| Declines ODDS (%) | 3 days ago 74% | 3 days ago 61% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 47% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s).
- DXCM’s TA Score: 5 bullish, 5 bearish.
- ISRG’s TA Score: 4 bullish, 4 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а -3.50% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +4.81% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.17%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +12.16%.
Reported Earning Dates
DXCM is expected to report earnings on Feb 11, 2027.
ISRG is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (-3.27% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.17% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -5.98% | ||
| ISRG - DXCM | 46% Loosely correlated | -3.36% | ||
| ALGN - DXCM | 44% Loosely correlated | +4.16% | ||
| LIVN - DXCM | 42% Loosely correlated | -1.26% | ||
| PODD - DXCM | 41% Loosely correlated | -6.16% | ||
| NVST - DXCM | 40% Loosely correlated | +0.84% | ||
More | ||||